Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Apremilast - SMC 1052/15 -Formulary Group advice will be published by 1st September 2015. (Indication: for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)).

Apremilast - SMC 1053/15 - Formulary Group advice will be published by 1st September 2015. (Indication: alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy).

Bevacizumab - FG1 371/14 - Formulary Group advice will be published by 1st September 2015. (Indication: colorectal cancer)

Ceftobiprole - SMC 943/14 -Formulary Group advice will be published by 1st September 2015. (Indication: treatment of the following infections in adults: hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP); community-acquired pneumonia (CAP)).

Cetuximab - SMC 1012/14 - in progress.  (Indication: treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer).

Darunavir/cobicistat (Rezolsta®) - SMC 1081/15 - Formulary Group advice will be published by 1st September 2015. (Indication:In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use).

Magnesium aspartate dihydrate - SMC 1042/15 -Formulary Group advice will be published by 1st September 2015. (Indication: for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor).

Moviprep - FG1 388/15 - in progress. (Indication: bowel cleansing preparation).

Nintedanib - SMC 1027/15 - in progress. (Indication: in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy). 

Palonosetron - SMC 1073/15 -Formulary Group advice will be published by 1st September 2015.  (Indication: prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older).

Tedizolid phosphate - SMC 1080/15 - Formulary Group advice will be published by 1st September 2015. (Indication:The treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults).

Tiotropium - SMC 1028/15 - Formulary Group advice will be published by 1st September 2015. (Indication: As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »